Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: geneguru who wrote (2313)	10/2/2013 11:12:01 PM
From: scaram(o)uche	Respond to of 2344

It might not be new, but it's obvious that new stuff will be presented at the meeting. Fun new stuff..... "Exploratory analyses were done for treatment interaction for HLA-A02, -DRB4 and -B08. Baseline peripheral blood anti-nuclear antibodies (ANA), serum MUC1 (sMUC1), lymphocyte count and neutrophil:lymphocyte ratio (NLR) currently are being explored." "Detailed biomarker results will be presented." Never can tell, we might get some insight into the required enrollment for restart. RNAi.... certain that someone here will have ideas??..... Subject 26145 edit: oh, I see.... ont-10, and the old mouse poster. I get it now. Yes, that's "old stuff". :-)